Clinical Trial Update: VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial results are reported for aflibercept (VEGF Trap) in patients with unresectable recurrent melanoma (Stage III or Stage IV), with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intraocular Melanoma
• Melanoma

Drugs mentioned

• Zaltrap (ramucirumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2015-02-04